ANI Pharmaceuticals (ANIP) Lifted to “Buy” at ValuEngine
ValuEngine upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a research note released on Friday morning.
Several other equities research analysts also recently weighed in on ANIP. Canaccord Genuity set a $82.00 price objective on shares of ANI Pharmaceuticals and gave the stock a buy rating in a report on Tuesday. TheStreet downgraded shares of ANI Pharmaceuticals from a b rating to a c+ rating in a report on Tuesday, February 20th. BidaskClub downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, February 22nd. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 price objective for the company in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $72.25.
Shares of ANI Pharmaceuticals (NASDAQ ANIP) traded up $1.67 on Friday, hitting $62.69. 173,742 shares of the stock traded hands, compared to its average volume of 153,196. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $74.70. The firm has a market capitalization of $749.88, a P/E ratio of 59.14 and a beta of 2.75. The company has a current ratio of 3.36, a quick ratio of 2.39 and a debt-to-equity ratio of 1.13.
A number of hedge funds have recently bought and sold shares of ANIP. Bank of Montreal Can lifted its holdings in ANI Pharmaceuticals by 681.8% in the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock worth $156,000 after purchasing an additional 2,100 shares during the period. SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals in the third quarter worth about $197,000. Millennium Management LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter worth about $210,000. Violich Capital Management Inc. bought a new stake in ANI Pharmaceuticals in the third quarter worth about $217,000. Finally, Driehaus Capital Management LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter worth about $220,000. 53.92% of the stock is owned by institutional investors and hedge funds.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.